BioAmber Inc. (NYSE:BIOA) is scheduled to be issuing its quarterly earnings data before the market opens on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.

BioAmber (NYSE:BIOA) last issued its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The business had revenue of $4.12 million during the quarter, compared to the consensus estimate of $4.09 million. BioAmber had a negative return on equity of 56.55% and a negative net margin of 221.82%.

BioAmber Inc. (NYSE:BIOA) opened at $0.53 on Monday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.03 and a current ratio of 1.50.

ILLEGAL ACTIVITY NOTICE: “BioAmber Inc. (BIOA) to Release Quarterly Earnings on Tuesday” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.watchlistnews.com/bioamber-inc-bioa-to-release-quarterly-earnings-on-tuesday/1681644.html.

A hedge fund recently raised its stake in BioAmber stock. Vanguard Group Inc. increased its stake in shares of BioAmber Inc. (NYSE:BIOA) by 9.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 303,360 shares of the biotechnology company’s stock after buying an additional 27,278 shares during the quarter. Vanguard Group Inc. owned about 0.82% of BioAmber worth $780,000 as of its most recent SEC filing. Institutional investors and hedge funds own 36.29% of the company’s stock.

A number of brokerages have recently issued reports on BIOA. Cowen and Company set a $3.00 price target on BioAmber and gave the stock a “hold” rating in a research report on Monday, July 17th. Zacks Investment Research downgraded BioAmber from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Finally, ValuEngine downgraded BioAmber from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 8th.

About BioAmber

BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.

Earnings History for BioAmber (NYSE:BIOA)

Receive News & Ratings for BioAmber Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAmber Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.